Zoledronic acid reduces the incidence of new developed compression fractures after vertebroplasty or kyphoplasty in patients with osteoporotic vertebral compression fractures

Published: 01-07-2021| Version 1 | DOI: 10.17632/b5y8dc399r.1
Contributor:
Bo Liao

Description

The research aims to determine the efficacy of once-yearly intravenous zoledronic acid in reducing the risk of osteoporotic vertebral compression fractures (OVCFs) after treatment by percutaneous vertebroplasty (PVP) and percutaneous kyphoplasty (PKP). A total of 144 patients were diagnosed with osteoporotic vertebral compression fractures from January 2012 to December 2017. These patients received PVP or PKP treatment at the Department of Orthopedics, Tangdu Hospital, Air Force Medical University. The painful vertebrae were confirmed based on clinical symptoms and a T2-weighted fat-suppression magnetic resonance image. The BMD was measured by dual-energy X-ray absorptiometry (DXA). However, 13 patients were not followed up for more than one year. The remaining 131 patients with at least one year follow-up were enrolled in the study.

Files